The stock of TESARO Inc (NASDAQ:TSRO) reached all time high today, Nov, 2 and still has $168.51 target or 37.00% above today’s $123.00 share price. This indicates more upside for the $6.35 billion company. This technical setup was reported by Barchart.com. If the $168.51 PT is reached, the company will be worth $2.35B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 1.08 million shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 175.13% since March 31, 2016 and is uptrending. It has outperformed by 172.61% the S&P500.
Analysts await TESARO Inc (NASDAQ:TSRO) to report earnings on November, 3. They expect $-1.92 earnings per share, down 15.66% or $0.26 from last year’s $-1.66 per share. After $-1.28 actual earnings per share reported by TESARO Inc for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 12 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 92% are positive. Tesaro Inc has been the topic of 20 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The firm has “Strong-Buy” rating given on Tuesday, September 1 by Raymond James. The stock of TESARO Inc (NASDAQ:TSRO) earned “Buy” rating by Lake Street on Friday, February 5. On Thursday, March 17 the stock rating was initiated by Citigroup with “Buy”. The firm earned “Neutral” rating on Tuesday, August 30 by Bank of America. The stock has “Outperform” rating given by Credit Suisse on Friday, May 13. The stock of TESARO Inc (NASDAQ:TSRO) earned “Outperform” rating by Wells Fargo on Friday, December 4. The firm has “Buy” rating given on Friday, August 5 by Mizuho. On Monday, August 24 the stock rating was initiated by Leerink Swann with “Outperform”. The company was maintained on Friday, August 5 by Wedbush. Bank of America upgraded the shares of TSRO in a report on Monday, October 10 to “Buy” rating.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.55 in Q2 2016. Its up 0.32, from 1.23 in 2016Q1. The ratio improved, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
The New York-based Suffolk Cap Management Limited Liability has invested 2.29% in TESARO Inc (NASDAQ:TSRO). The New York-based Teachers Advisors has invested 0.01% in TESARO Inc (NASDAQ:TSRO). Royal Commercial Bank Of Canada last reported 0% of its portfolio in the stock. Ghost Tree Capital Limited Liability Corporation, a New York-based fund reported 50,000 shares. Ecor1 Cap Ltd Liability Corporation reported 9,200 shares or 0.3% of all its holdings. Hatteras Funds Ltd Llc holds 7.19% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 15,310 shares. The Connecticut-based Quantitative Systematic Strategies Lc has invested 0.11% in TESARO Inc (NASDAQ:TSRO). Deutsche Financial Bank Ag holds 0.02% or 377,176 shares in its portfolio. Moreover, Massachusetts Fincl Serv Ma has 0.01% invested in TESARO Inc (NASDAQ:TSRO) for 196,651 shares. Cormorant Asset Management Llc last reported 4.33% of its portfolio in the stock. Two Sigma Securities Ltd Liability Corp has 0.31% invested in the company for 6,855 shares. Rhumbline Advisers last reported 24,759 shares in the company. California State Teachers Retirement Systems accumulated 51,584 shares or 0.01% of the stock. Geode Capital Management Ltd Liability Company reported 237,044 shares or 0.01% of all its holdings. Alliancebernstein Ltd Partnership has 768,610 shares for 0.06% of their US portfolio.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 5 selling transactions for $4.39 million net activity. English Edward C also sold $285,274 worth of TESARO Inc (NASDAQ:TSRO) shares. Huber Martin H. Jr. sold $44,113 worth of TESARO Inc (NASDAQ:TSRO) on Wednesday, September 21. 12,500 shares were sold by Hanke Jeffrey H., worth $929,321 on Thursday, June 30.
More news for TESARO Inc (NASDAQ:TSRO) were recently published by: Fool.com, which released: “Tesaro Inc. Is Flying High Today (and Could Go Higher From Here)” on October 10, 2016. Investorplace.com‘s article titled: “Why Alphabet Inc (GOOG), Mylan NV (MYL) And Tesaro Inc (TSRO) Are 3 of Today’s …” and published on October 10, 2016 is yet another important article.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.